BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

Kennedy, R.D., Quinn, J.E., Johnston, P.G. and Harkin, D.P. (2002) BRCA1: mechanisms of inactivation and implications for management of patients. Lancet, 360, 1007–1014.

Husain, A., He, G., Venkatraman, E.S. and Spriggs, D.R. (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res., 58, 1120–1123.

Abbott, D.W., Thompson, M.E., Robinson-Benion, C., Tomlinson, G., Jensen, R.A. and Holt, J.T. (1999) BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J. Biol. Chem., 274, 18808–18812.

Mullan, P.B., Quinn, J.E., Gilmore, P.M., McWilliams, S., Andrews, H., Gervin, C., McCabe, N., McKenna, S., White, P., Song, Y.H. et al. (2001) BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene, 20, 6123–6131.

Lotti, L.V., Ottini, L., D'Amico, C., Gradini, R., Cama, A., Belleudi, F., Frati, L., Torrisi, M.R. and Mariani-Costantini, R. (2002) Subcellular localization of the BRCA1 gene product in mitotic cells. Genes, Chromosomes Cancer, 35, 193–203.

Harkin, D.P., Bean, J.M., Miklos, D., Song, Y.H., Truong, V.B., Englert, C., Christians, F.C., Ellisen, L.W., Maheswaran, S., Oliner, J.D. et al. (1999) Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell, 97, 575–586.

Potapova, O., Haghighi, A., Bost, F., Liu, C., Birrer, M.J., Gjerset, R. and Mercola, D. (1997) The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem., 272, 14041–14044.

Lafarge, S., Sylvain, V., Ferrara, M. and Bignon, Y.J. (2001)Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene, 20, 6597–6606.

Tomlinson, G.E., Chen, T.T.L., Stastny, V.A., Virmani, A.K., Spillman, M.A., Tonk, V., Blum, J.L., Schneider, N.R., Wistuba, I.I., Shay, J.W. et al. (1998) Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res., 58, 3237–3242.

Quinn, J.E., Kennedy, R.D., Mullan, P.B., Gilmore, P.M., Carty, M., Johnston, P.G. and Harkin, D.P. (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res., 63, 6221–6228.

Brodie, S.G., Xu, X., Qiao, W., Li, W.M., Cao, L. and Deng, C.X. (2001) Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene, 20, 7514–7523.

Seery, L.T., Knowlden, J.M., Gee, J.M.W., Robertson, J.F.R., Kenny, F.S., Ellis, I.O. and Nicholson, R.I. (1999) BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int. J. Cancer (Pred. Oncol.), 84, 258–262.

Egawa, C., Miyoshi, Y., Takamura, Y., Taguchi, T., Tamaki, Y. and Noguchi, S. (2001) Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int. J. Cancer (Pred. Oncol.), 95, 255–259.

Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M.J. (2004) Cancer statistics, 2003. CA Cancer J. Clin., 54, 8–29.

Mountain, C.F. (1997) Revisions in the international system for staging lung cancer. Chest, 111, 1710–1717.

Pass, H.I., Pogrebniak, H.W., Steinberg, S.M., Mulshine, J. and Minna, J. (1992) Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann. Thor. Surg., 53, 992–998.

Rosell, R., Gómez-Codina, J., Camps, C., Maestre, J., Padilla, J., Cantó, A, Mate, J.L., Li Shanrong, Roig J., Olazábal, A. et al. (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med., 330, 153–158.

Martini, N., Kris, M.G., Flehinger, B.J., Gralla, R.J., Bains, M.S., Burt, M.E., Heelan, R., McCormack, P.M., Pisters, K.M.W., Rigas, J.R. et al. (1993) Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg., 55, 1365–1374.

Aloyz, R., Xu, Z.Y., Bello, V., Bergeon, J., Han, F.Y., Yan, Y., Malapetsa, A., Alaoui-Jamali, M.A., Duncan, A.M.V. and Panasci, L. (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res., 62, 5457–5462.

Furuta, T., Ueda, T., Aune, G., Sarasin, A., Kraemer, K.H. and Pommier, Y. (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res., 62, 4899–4902.

Lord, R.V.N., Brabender, J., Gandara, D., Alberola, V., Camps, C., Domine, M., Cardenal, F., Sanchez, J.M., Gumerlock, P.H., Taron, M. et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin. Cancer Res., 8, 2286–2291.

Rosell, R., Scagliotti, G., Danenberg, K.D., Lord, R., Bepler, G., Novello, S., Cooc, J., Crino, L., Sancehz, J.J., Taron, M. et al. (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene, 22, 3548–3553.

Rosell, R., Danenberg, K.D., Alberola, V., Bepler, G., Sanchez, J.J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P. et al. (2004) Ribonucleotide reductase mRNA expression and survival in gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin. Cancer Res., 10, 1318–1325.

LePage, F., Randrianarison, V., Marot, D., Cabannes, J., Perricaudet, M., Feunteun, J. and Sarasin, A. (2000) BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res., 60, 5548–5552.

Einspahr, J.G., Krouse, R.S., Yochim, J.M., Danenberg, P.V., Danenberg, K.D., Bhattacharyya, A.K., Martinez, M.E. and Alberts, D.S. (2003) Association between cyclooxygenase expression and colorectal adenoma characteristics. Cancer Res., 63, 3891–3893.

Rice, J.C., Massey-Brown, K.S. and Futscher, B.W. (1998) Aberrant methylation of the BRCA1CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene, 17, 1807–1812.

Esteller, M., Silva, J.M., Domínguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, Prat, J., Harkes, I.C., Repasky, E.A. et al. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst., 92, 564–569.

Hussain, S., Uit E, Huber, P.A.J., Medhurst, A.L., Ashworth, A. and Mathew, C.G. (2003). Direct interaction of the Fanconi with BRCA2/FANCD1. Hum. Mol. Genet., 12, 2503–2510

Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S.V., Mathew, C.G., Joenje, H., Mok, S.C and D'Andrea, A.D. (2003) Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med., 9, 568–574.

Wei, Q., Cheng, L., Amos, C.I., Wang, L.E., Guo, Z., Hong, W.K.H and Spitz, M.R. (2000). Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J. Natl Cancer Inst., 92, 1764–1772.

Zeng-Rong, N., Paterson, J., Alpert, L., Tsao, M.S., Viallet, J. and Alaoui-Jamali, M.A. (1995) Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res., 55, 4760–4764.

Bosken, C.H., Wei, Q., Amos, C.I. and Spitz, M.R. (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl Cancer Inst., 94, 1091–1099.

Schiller, J.H., Harrington, D., Velan, C.P., Langer, C., Sandler, A., Krrok, J., Zhu, J. and Johnson, D.H. (2002) Comparison of tour chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 346, 92–98.

Gatzemeier, U., von Pawel, J., Gottfried, M., ten Velde, G.P.M., Mattson, K., DeMarinis, F., Harper, P., Salvati, F., Robinet, G., Lucenti, A. et al. (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 18, 3390–3399.

Georgoulias, V., Ardavanis, A., Agelidou, A., Agelidou, M., Chandrinos, V., Tsaroucha, E., Toumbis, M., Kouroussis, C., Syrigos, K., Polyzos, A. et al. (2004) Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial. J. Clin. Oncol., 22, 2602–2609.

Specht, K., Richter, T., Müller, U., Walch, A., Werner, M. and Hofler, H. (2001) Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am. J. Pathol., 158, 419–429.

Krafft, A.E., Duncan, B.W., Bijwaard, K.E., Taubenberger, J.K. and Lichy, J.H. (1997) Optimization of the isolation and amplification of RNA from formalin fixed, paraffin-embedded tissue: The Armed Forces Institute of Pathology experience and literature review. Mol. Diagn., 3, 217–230.